Schwarz, DS, Hutvagner, G, Du, T, Xu, Z, Aronin, N, Zamore, PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003, 115:199–208.
Baulcombe, D. Overview of RNA interference and related processes. Curr Protoc Mol Biol 2003, Chapter 26:Unit 26.21.
Ozcan, G, Ozpolat, B, Coleman, RL, Sood, AK, Lopez‐Berestein, G. Preclinical and clinical development of siRNA‐based therapeutics. Adv Drug Deliv Rev 2015, 87:108–119.
Soutschek, J, Akinc, A, Bramlage, B, Charisse, K, Constien, R, Donoghue, M, Elbashir, S, Geick, A, Hadwiger, P, Harborth, J, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173–178.
Pecot, CV, Calin, GA, Coleman, RL, Lopez‐Berestein, G, Sood, AK. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011, 11:59–67.
Chen, SH, Zhaori, G. Potential clinical applications of siRNA technique: benefits and limitations. Eur J Clin Invest 2011, 41:221–232.
Hagiwara, K, Ochiya, T, Kosaka, N. A paradigm shift for extracellular vesicles as small RNA carriers: from cellular waste elimination to therapeutic applications. Drug Deliv Transl Res 2014, 4:31–37.
El Andaloussi, S, Lakhal, S, Mager, I, Wood, MJ. Exosomes for targeted siRNA delivery across biological barriers. Adv Drug Deliv Rev 2013, 65:391–397.
Stoorvogel, W. Functional transfer of microRNA by exosomes. Blood 2012, 119:646–648.
Conde, J, Artzi, N. Are RNAi and miRNA therapeutics truly dead? Trends Biotechnol 2015, 33:141–144.
Bobbin, ML, Rossi, JJ. RNA interference (RNAi)‐based therapeutics: delivering on the promise? Annu Rev Pharmacol Toxicol 2016, 56:103–122.
Davis, ME, Zuckerman, JE, Choi, CH, Seligson, D, Tolcher, A, Alabi, CA, Yen, Y, Heidel, JD, Ribas, A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067–1070.
Zuckerman, JE, Gritli, I, Tolcher, A, Heidel, JD, Lim, D, Morgan, R, Chmielowski, B, Ribas, A, Davis, ME, Yen, Y. Correlating animal and human phase Ia/Ib clinical data with CALAA‐01, a targeted, polymer‐based nanoparticle containing siRNA. Proc Natl Acad Sci USA 2014, 111:11449–11454.
Gonzalez, V, Moreno‐Montañés, J, Sádaba, B, Ruz, V, Jímenez, AI. SYL1001 for treatment of ocular discomfort in dry eye: safety and tolerance (phase I study). Invest Ophthalmol Vis Sci 2012, 53:575.
Martinez, T, Gonzalez, MV, Roehl, I, Wright, N, Paneda, C, Jimenez, AI. In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol Ther 2014, 22:81–91.
Fitzgerald, K, Frank‐Kamenetsky, M, Shulga‐Morskaya, S, Liebow, A, Bettencourt, BR, Sutherland, JE, Hutabarat, RM, Clausen, VA, Karsten, V, Cehelsky, J, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single‐blind, placebo‐controlled, phase 1 trial. Lancet 2014, 383:60–68.
Zimmermann, T, Karsten, V, Harrop, J, Chan, A, Chiesa, J, Peters, G, Falzone, R, Cehelsky, J, Nochur, S, Vaishnaw, A, et al. Phase I first‐in‐humans trial of ALN‐TTRsc, a novel RNA interference therapeutic for the treatment of familial amyloidotic cardiomyopathy (FAC). J Card Fail 2013, 19:S66.
Coelho, T, Adams, D, Silva, A, Lozeron, P, Hawkins, PN, Mant, T, Perez, J, Chiesa, J, Warrington, S, Tranter, E, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013, 369:819–829.
Golan, T, Khvalevsky, EZ, Hubert, A, Gabai, RM, Hen, N, Segal, A, Domb, A, Harari, G, David, EB, Raskin, S, et al. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget 2015, 6:24560–24570.
Cervantes, A, Alsina, M, Tabernero, J, Infante, JR, LoRusso, P, Shapiro, G, Paz‐Ares, LG, Falzone, R, Hill, J, Cehelsky, J, et al. Phase I dose‐escalation study of ALN‐VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. In: Annual Meeting Proceedings, 2011.
Gish, RG, Yuen, MF, Chan, HL, Given, BD, Lai, CL, Locarnini, SA, Lau, JY, Wooddell, CI, Schluep, T, Lewis, DL. Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. Antiviral Res 2015, 121:97–108.
Leachman, SA, Hickerson, RP, Schwartz, ME, Bullough, EE, Hutcherson, SL, Boucher, KM, Hansen, CD, Eliason, MJ, Srivatsa, GS, Kornbrust, DJ, et al. First‐in‐human mutation‐targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther 2010, 18:442–446.
Mousa, SA, Mousa, SS. Current status of vascular endothelial growth factor inhibition in age‐related macular degeneration. BioDrugs 2010, 24:183–194.
Solano, EC, Kornbrust, DJ, Beaudry, A, Foy, JW, Schneider, DJ, Thompson, JD. Toxicological and pharmacokinetic properties of QPI‐1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. Nucleic Acid Ther 2014, 24:258–266.
Ramanathan, RK, Hamburg, SI, Borad, MJ, Seetharam, M, Kundranda, MN, Lee, P, Fredlund, P, Gilbert, M, Mast, C, Semple, SC, et al. Abstract LB‐289: a phase I dose escalation study of TKM‐080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors. Cancer Res 2013, 73:LB‐289.
Garba, AO, Mousa, SA. Bevasiranib for the treatment of wet, age‐related macular degeneration. Ophthalmol Eye Dis 2010, 2:75–83.
Thompson, JD, Kornbrust, DJ, Foy, JW, Solano, EC, Schneider, DJ, Feinstein, E, Molitoris, BA, Erlich, S. Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration. Nucleic Acid Ther 2012, 22:255–264.
Schultheis, B, Strumberg, D, Santel, A, Vank, C, Gebhardt, F, Keil, O, Lange, C, Giese, K, Kaufmann, J, Khan, M, et al. First‐in‐human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J Clin Oncol 2014, 32:4141–4148.
Nguyen, QD, Schachar, RA, Nduaka, CI, Sperling, M, Basile, AS, Klamerus, KJ, Chi‐Burris, K, Yan, E, Paggiarino, DA, Rosenblatt, I, et al. Phase 1 dose‐escalation study of a siRNA targeting the RTP801 gene in age‐related macular degeneration patients. Eye (Lond) 2012, 26:1099–1105.
Nguyen, QD, Schachar, RA, Nduaka, CI, Sperling, M, Klamerus, KJ, Chi‐Burris, K, Yan, E, Paggiarino, DA, Rosenblatt, I, Aitchison, R, et al. Evaluation of the siRNA PF‐04523655 versus ranibizumab for the treatment of neovascular age‐related macular degeneration (MONET Study). Ophthalmology 2012, 119:1867–1873.
Nguyen, QD, Schachar, RA, Nduaka, CI, Sperling, M, Basile, AS, Klamerus, KJ, Chi‐Burris, K, Yan, E, Paggiarino, DA, Rosenblatt, I, et al. Dose‐ranging evaluation of intravitreal siRNA PF‐04523655 for diabetic macular edema (the DEGAS study). Invest Ophthalmol Vis Sci 2012, 53:7666–7674.
Thakur, A, Fitzpatrick, S, Zaman, A, Kugathasan, K, Muirhead, B, Hortelano, G, Sheardown, H. Strategies for ocular siRNA delivery: potential and limitations of non‐viral nanocarriers. J Biol Eng 2012, 6:7.
Morjaria, R, Chong, NV. Pharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edema. Expert Opin Drug Metab Toxicol 2014, 10:1185–1192.
Wang, Z, Rao, DD, Senzer, N, Nemunaitis, J. RNA interference and cancer therapy. Pharm Res 2011, 28:2983–2995.
van den Boorn, JG, Schlee, M, Coch, C, Hartmann, G. SiRNA delivery with exosome nanoparticles. Nat Biotechnol 2011, 29:325–326.
Shih, YM, Sun, CP, Chou, HH, Wu, TH, Chen, CC, Wu, PY, Enya Chen, YC, Bissig, KD, Tao, MH. Combinatorial RNA interference therapy prevents selection of pre‐existing HBV variants in human liver chimeric mice. Sci Rep 2015, 5:15259.
Dobrovolskaia, MA, Aggarwal, P, Hall, JB, McNeil, SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 2008, 5:487–495.
Hacein‐Bey‐Abina, S, von Kalle, C, Schmidt, M, Le Deist, F, Wulffraat, N, McIntyre, E, Radford, I, Villeval, JL, Fraser, CC, Cavazzana‐Calvo, M, et al. A serious adverse event after successful gene therapy for X‐linked severe combined immunodeficiency. N Engl J Med 2003, 348:255–256.
Thery, C, Zitvogel, L, Amigorena, S. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002, 2:569–579.
Mathivanan, S, Ji, H, Simpson, RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteomics 2010, 73:1907–1920.
Simons, M, Raposo, G. Exosomes—vesicular carriers for intercellular communication. Curr Opin Cell Biol 2009, 21:575–581.
Colombo, M, Raposo, G, Thery, C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 2014, 30:255–289.
Kowal, J, Tkach, M, Thery, C. Biogenesis and secretion of exosomes. Curr Opin Cell Biol 2014, 29:116–125.
Hanson, PI, Cashikar, A. Multivesicular body morphogenesis. Annu Rev Cell Dev Biol 2012, 28:337–362.
Valadi, H, Ekstrom, K, Bossios, A, Sjostrand, M, Lee, JJ, Lotvall, JO. Exosome‐mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9:654–659.
Zhang, Y, Liu, D, Chen, X, Li, J, Li, L, Bian, Z, Sun, F, Lu, J, Yin, Y, Cai, X, et al. Secreted monocytic miR‐150 enhances targeted endothelial cell migration. Mol Cell 2010, 39:133–144.
Kosaka, N, Iguchi, H, Yoshioka, Y, Takeshita, F, Matsuki, Y, Ochiya, T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 2010, 285:17442–17452.
Trajkovic, K, Hsu, C, Chiantia, S, Rajendran, L, Wenzel, D, Wieland, F, Schwille, P, Brugger, B, Simons, M. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 2008, 319:1244–1247.
Villarroya‐Beltri, C, Gutierrez‐Vazquez, C, Sanchez‐Cabo, F, Perez‐Hernandez, D, Vazquez, J, Martin‐Cofreces, N, Martinez‐Herrera, DJ, Pascual‐Montano, A, Mittelbrunn, M, Sanchez‐Madrid, F. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat Commun 2013, 4:2980.
Fabbri, M, Paone, A, Calore, F, Galli, R, Gaudio, E, Santhanam, R, Lovat, F, Fadda, P, Mao, C, Nuovo, GJ, et al. MicroRNAs bind to Toll‐like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci USA 2012, 109:E2110–E2116.
Lehmann, SM, Kruger, C, Park, B, Derkow, K, Rosenberger, K, Baumgart, J, Trimbuch, T, Eom, G, Hinz, M, Kaul, D, et al. An unconventional role for miRNA: let‐7 activates Toll‐like receptor 7 and causes neurodegeneration. Nat Neurosci 2012, 15:827–835.
Alvarez‐Erviti, L, Seow, Y, Yin, H, Betts, C, Lakhal, S, Wood, MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011, 29:341–345.
Pan, Q, Ramakrishnaiah, V, Henry, S, Fouraschen, S, de Ruiter, PE, Kwekkeboom, J, Tilanus, HW, Janssen, HL, van der Laan, LJ. Hepatic cell‐to‐cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi). Gut 2012, 61:1330–1339.
Zhang, Y, Li, L, Yu, J, Zhu, D, Zhang, Y, Li, X, Gu, H, Zhang, CY, Zen, K. Microvesicle‐mediated delivery of transforming growth factor β1 siRNA for the suppression of tumor growth in mice. Biomaterials 2014, 35:4390–4400.
Kumar, L, Verma, S, Vaidya, B, Gupta, V. Exosomes: natural carriers for siRNA delivery. Curr Pharm Des 2015, 21:4556–4565.
Chen, X, Liang, H, Zhang, J, Zen, K, Zhang, CY. Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol 2012, 22:125–132.
Lässer, C. Exosomes in diagnostic and therapeutic applications: biomarker, vaccine and RNA interference delivery vehicle. Expert Opin Biol Ther 2015, 15:103–117.
Liang, H, Gong, F, Zhang, S, Zhang, CY, Zen, K, Chen, X. The origin, function, and diagnostic potential of extracellular microRNAs in human body fluids. Wiley Interdiscip Rev RNA 2014, 5:285–300.
Yin, Y, Cai, X, Chen, X, Liang, H, Zhang, Y, Li, J, Wang, Z, Chen, X, Zhang, W, Yokoyama, S, et al. Tumor‐secreted miR‐214 induces regulatory T cells: a major link between immune evasion and tumor growth. Cell Res 2014, 24:1164–1180.
Zhou, W, Fong, MY, Min, Y, Somlo, G, Liu, L, Palomares, MR, Yu, Y, Chow, A, O`Connor, ST, Chin, AR, et al. Cancer‐secreted miR‐105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 2014, 25:501–515.
Sun, T, Kalionis, B, Lv, G, Xia, S, Gao, W. Role of exosomal noncoding RNAs in lung carcinogenesis. Biomed Res Int 2015, 2015:125807.
Wei, Y, Lai, X, Yu, S, Chen, S, Ma, Y, Zhang, Y, Li, H, Zhu, X, Yao, L, Zhang, J. Exosomal miR‐221/222 enhances tamoxifen resistance in recipient ER‐positive breast cancer cells. Breast Cancer Res Treat 2014, 147:423–431.
Pegtel, DM, Cosmopoulos, K, Thorley‐Lawson, DA, van Eijndhoven, MA, Hopmans, ES, Lindenberg, JL, de Gruijl, TD, Wurdinger, T, Middeldorp, JM. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci USA 2010, 107:6328–6333.
Lagana, A, Russo, F, Veneziano, D, Bella, SD, Giugno, R, Pulvirenti, A, Croce, CM, Ferro, A. Extracellular circulating viral microRNAs: current knowledge and perspectives. Front Genet 2013, 4:120.
Verweij, FJ, van Eijndhoven, MA, Middeldorp, J, Pegtel, DM. Analysis of viral microRNA exchange via exosomes in vitro and in vivo. Methods Mol Biol 2013, 1024:53–68.
Mittelbrunn, M, Gutierrez‐Vazquez, C, Villarroya‐Beltri, C, Gonzalez, S, Sanchez‐Cabo, F, Gonzalez, MA, Bernad, A, Sanchez‐Madrid, F. Unidirectional transfer of microRNA‐loaded exosomes from T cells to antigen‐presenting cells. Nat Commun 2011, 2:282.
Chen, Y, Chen, J, Wang, H, Shi, J, Wu, K, Liu, S, Liu, Y, Wu, J. HCV‐induced miR‐21 contributes to evasion of host immune system by targeting MyD88 and IRAK1. PLoS Pathog 2013, 9:e1003248.
Thery, C, Regnault, A, Garin, J, Wolfers, J, Zitvogel, L, Ricciardi‐Castagnoli, P, Raposo, G, Amigorena, S. Molecular characterization of dendritic cell‐derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol 1999, 147:599–610.
Tian, Y, Li, S, Song, J, Ji, T, Zhu, M, Anderson, GJ, Wei, J, Nie, G. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 2014, 35:2383–2390.
Koppers‐Lalic, D, Hogenboom, MM, Middeldorp, JM, Pegtel, DM. Virus‐modified exosomes for targeted RNA delivery; a new approach in nanomedicine. Adv Drug Deliv Rev 2013, 65:348–356.
Vallhov, H, Gutzeit, C, Johansson, SM, Nagy, N, Paul, M, Li, Q, Friend, S, George, TC, Klein, E, Scheynius, A, et al. Exosomes containing glycoprotein 350 released by EBV‐transformed B cells selectively target B cells through CD21 and block EBV infection in vitro. J Immunol 2011, 186:73–82.
Liu, Y, Li, D, Liu, Z, Zhou, Y, Chu, D, Li, X, Jiang, X, Hou, D, Chen, X, Chen, Y, et al. Targeted exosome‐mediated delivery of opioid receptor μ siRNA for the treatment of morphine relapse. Sci Rep 2015, 5:17543.
El‐Andaloussi, S, Lee, Y, Lakhal‐Littleton, S, Li, J, Seow, Y, Gardiner, C, Alvarez‐Erviti, L, Sargent, IL, Wood, MJ. Exosome‐mediated delivery of siRNA in vitro and in vivo. Nat Protoc 2012, 7:2112–2126.
Banizs, AB, Huang, T, Dryden, K, Berr, SS, Stone, JR, Nakamoto, RK, Shi, W, He, J. In vitro evaluation of endothelial exosomes as carriers for small interfering ribonucleic acid delivery. Int J Nanomedicine 2014, 9:4223–4230.
Kooijmans, SA, Stremersch, S, Braeckmans, K, de Smedt, SC, Hendrix, A, Wood, MJ, Schiffelers, RM, Raemdonck, K, Vader, P. Electroporation‐induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles. J Control Release 2013, 172:229–238.
Morishita, M, Takahashi, Y, Nishikawa, M, Sano, K, Kato, K, Yamashita, T, Imai, T, Saji, H, Takakura, Y. Quantitative analysis of tissue distribution of the B16BL6‐derived exosomes using a streptavidin‐lactadherin fusion protein and iodine‐125‐labeled biotin derivative after intravenous injection in mice. J Pharm Sci 2015, 104:705–713.
Takahashi, Y, Nishikawa, M, Shinotsuka, H, Matsui, Y, Ohara, S, Imai, T, Takakura, Y. Visualization and in vivo tracking of the exosomes of murine melanoma B16‐BL6 cells in mice after intravenous injection. J Biotechnol 2013, 165:77–84.
Lai, CP, Mardini, O, Ericsson, M, Prabhakar, S, Maguire, CA, Chen, JW, Tannous, BA, Breakefield, XO. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. ACS Nano 2014, 8:483–494.
Shtam, TA, Kovalev, RA, Varfolomeeva, EY, Makarov, EM, Kil, YV, Filatov, MV. Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell Commun Signal 2013, 11:88.
Olson, SD, Kambal, A, Pollock, K, Mitchell, G‐M, Stewart, H, Kalomoiris, S, Cary, W, Nacey, C, Pepper, K, Nolta, JA. Examination of mesenchymal stem cell‐mediated RNAi transfer to Huntington`s disease affected neuronal cells for reduction of huntingtin. Mol Cell Neurosci 2012, 49:271–281.
Wahlgren, J, Karlson, TDL, Brisslert, M, Sani, FV, Telemo, E, Sunnerhagen, P, Valadi, H. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res 2012, 40:e130.
Cooper, JM, Wiklander, PB, Nordin, JZ, Al‐Shawi, R, Wood, MJ, Vithlani, M, Schapira, AH, Simons, JP, El‐Andaloussi, S, Alvarez‐Erviti, L. Systemic exosomal siRNA delivery reduced α‐synuclein aggregates in brains of transgenic mice. Mov Disord 2014, 29:1476–1485.
Chen, TS, Arslan, F, Yin, Y, Tan, SS, Lai, RC, Choo, A, Padmanabhan, J, Lee, CN, De Kleijn, D, Lim, SK. Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC‐derived MSCs. J Transl Med 2011, 9:1471–1482.